Frederick Min, MD
Hematology & Oncology · Silver Spring, MDNPI 1366682429
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,830 of the $13,322 with a category attached, or 73.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 18.1%.
Across 424 payments — averaging $31.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$2K
- Rigel Pharmaceuticals, Inc.$1K
- Johnson & Johnson$834
- Novartis$782
- Incyte Corporation$497
- Merck$454
- plus $7K from 54 others
Across 125 payments — averaging $9107.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$404K
- Daiichi Sankyo Inc.$176K
- Novartis$169K
- Astrazeneca UK Limited$123K
- Genentech, Inc.$119K
- Seagen Inc.$80K
- plus $68K from 4 others
What the payments were for
- Consulting fees$2,28017%
- Speaking & faculty fees$1,0008%
- Food & beverage$9,83074%
- Education$2122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$2,280
- Tavalisse$1,000
- DEXCOM G7 GSS (161)$134
- EVENITY$122
How this compares
$13,322 in reported general payments places this provider in the 75th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 38 | $524,320 |
| LynparzaOlaparib | 35 | $498,397 |
| JakafiRuxolitinib Phosphate | 25 | $312,162 |
| LenvimaLenvatinib Mesylate | 11 | $276,452 |
| IbrancePalbociclib | 15 | $243,466 |
| ZejulaNiraparib Tosylate | 14 | $230,898 |
| Lenalidomide | 13 | $185,513 |
| Abiraterone Acetate | 29 | $123,543 |
| EliquisApixaban | 111 | $106,476 |
| XareltoRivaroxaban | 64 | $65,754 |
| Imatinib Mesylate | 28 | $26,104 |
| OzempicSemaglutide | 13 | $18,475 |
| Acyclovir | 69 | $1,109 |
| Levothyroxine Sodium | 27 | $933 |
| Dexamethasone | 55 | $677 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $111 | $524,32038 claims |
| AstraZenecaLynparza | $412 | $498,39735 claims |
| PfizerIbrance, Eliquis | $308 | $349,942126 claims |
| Incyte CorporationJakafi | $497 | $312,16225 claims |
| Eisai Inc.Lenvima | $2,416 | $276,45211 claims |
| GSKZejula | $290 | $230,89814 claims |
| Johnson & JohnsonXarelto | $834 | $65,75464 claims |
| Lilly USA, LLCOlanzapine | $179 | $16821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Silver Spring
- Kashif AliSilver Spring$987K
- Courtney AckermanSilver Spring$25K
- Kashif FirozviSilver Spring$17K
- Clara ChanSilver Spring$15K
- Ralph BocciaBethesda$3.1M
- Sandra SwainBethesda$1M
- Ani BalmanoukianBaltimore$842K
- Benjamin LevyBaltimore$578K
- Patrick FordeBaltimore$269K
- Noah HahnBaltimore$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.